REASSESSMENT DYNAMICS OF ORPHAN DRUGS IN GERMANY'S BENEFIT ASSESSMENT PROCESS

被引：0

作者：

Chavez, D. ^{[1
]}

Tolkmitt, F. ^{[2
]}

Mills, M. ^{[2
]}

Kanavos, P. ^{[1
]}

机构：

[1] London Sch Econ & Polit Sci, London, England

[2] Hive Hlth Optimum Ltd, London, England

来源：

VALUE IN HEALTH | 2024年 / 27卷 / 12期

关键词：

D O I：

暂无

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

PT7

引用

页码：S323 / S323

页数：1

共 50 条

[1] QUO VADIS BENEFIT ASSESSMENT FOR ORPHAN DRUGS IN GERMANY: THE END OF THE EXCEPTION?
Weiner, L.
Khonsari, R.
Walzer, S.
VALUE IN HEALTH, 2022, 25 (12) : S302 - S302
[2] AMNOG BENEFIT ASSESSMENT FOR ONCOLOGIC AND ORPHAN DRUGS IN GERMANY - IMPLICATIONS FOR PRICE DISCOUNTS
Theidel, U.
Wahlers, K.
Mittendorf, T.
VALUE IN HEALTH, 2014, 17 (07) : A645 - A645
[3] OUTCOMES OF BENEFIT ASSESSMENTS OF ORPHAN DRUGS WITHOUT ORPHAN DESIGNATION IN GERMANY
Frick, L.
Qiu, Z.
Schoenermark, M.
VALUE IN HEALTH, 2022, 25 (12) : S305 - S305
[4] EARLY BENEFIT ASSESSMENT OF ORPHAN DRUGS IN GERMANY: METHODOLOGICAL CHALLENGES AND IMPLICATIONS ON REIMBURSEMENT PRICE
Schneider, D.
Bot, D.
Ecker, T.
VALUE IN HEALTH, 2016, 19 (03) : A281 - A281
[5] REIMBURSEMENT OF ORPHAN DRUGS UNDER EARLY BENEFIT ASSESMENT IN GERMANY
Ecker, T.
Schneider, D.
Bot, D.
VALUE IN HEALTH, 2016, 19 (03) : A281 - A281
[6] G-BA benefit assessment of new orphan drugs in Germany: the first five years
Bouslouk, Meriem
EXPERT OPINION ON ORPHAN DRUGS, 2016, 4 (05): : 453 - 455
[7] COMPARISON OF ADDITIONAL BENEFIT RATING AND DRUG PRICES FOR ORPHAN DRUGS IN FRANCE AND GERMANY
Oku, Y.
Fukushima, A.
Dorey, J.
Toumi, M.
VALUE IN HEALTH, 2018, 21 : S107 - S107
[8] ADDITIONAL BENEFIT SCORING DURING HEALTH TECHNOLOGY ASSESSMENT IN GERMANY - ITS DRIVERS AND IMPACT ON PRICING AND DISCOUNT FOR ORPHAN DRUGS
Oku, Y.
Fukushima, A.
Dorey, J.
Toumi, M.
VALUE IN HEALTH, 2018, 21 : S85 - S86
[9] ORPHAN DRUGS ASSESSMENT IN GERMANY: A COMPARISON WITH OTHER INTERNATIONAL HTA AGENCIES
Mycka, J.
Dellamano, R.
Lobb, W.
Dellamano, L.
Dalal, N.
VALUE IN HEALTH, 2015, 18 (07) : A550 - A551
[10] FACTORS INFLUENCING THE SHI COSTS OF ORPHAN DRUGS AFTER THEIR RENEWED REGULAR BENEFIT ASSESSMENT DUE TO EXCEEDING THE SALES THRESHOLD IN GERMANY
Bruckel, S.
Reindl, S.
VALUE IN HEALTH, 2023, 26 (12) : S382 - S382

← 1 2 3 4 5 →